Key result
Targeting RAGE offers potential vascular protection against advanced glycation end product-driven microvascular damage in diabetes.
Answers are grounded in this paper and cite their sources.
Demonstrates how advanced glycation end products drive diabetic vascular injury via RAGE signaling, suggesting therapeutic targets for vascular protection.
The advanced glycation end products (AGEs) are a heterogeneous class of molecules, including the following main subgroups: bis(lysyl)imidazolium cross-links, hydroimidazolones, 3-deoxyglucosone derivatives, and monolysyl adducts. AGEs are increased in diabetes, renal failure, and aging. Microvascular lesions correlate with the accumulation of AGEs, as demonstrated in diabetic retinopathy or renal glomerulosclerosis. On endothelial cells, ligation of receptor for AGE (RAGE) by AGEs induces the expression of cell adhesion molecules, tissue factor, cytokines such as interleukin-6, and monocyte chemoattractant protein-1. A chief means by which AGEs via RAGE exert their effects is by generation of reactive oxygen species, at least in part via stimulation of NADPH oxidase. Diabetes-associated vascular dysfunction in vivo can be prevented by blockade of RAGE. Thus, agents that limit AGE formation, increase the catabolism of these species, or antagonize their binding to RAGE may provide new targets for vascular protection in diabetes.
No takes yet. Share an insight, caveat, or question.
Wautier et al. (2004) conducted a review in Diabetes, renal failure, and aging. Advanced glycation end products (AGEs) was evaluated. Advanced glycation end products promote microvascular lesions and vascular dysfunction, suggesting that RAGE blockade may provide new targets for vascular protection in diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: